| Literature DB >> 22481227 |
Pedro de la Oliva1, Cristina Schüffelmann, Ana Gómez-Zamora, Jesus Villar, Robert M Kacmarek.
Abstract
PURPOSE: To determine if neurally adjusted ventilatory assist (NAVA) improves asynchrony, ventilatory drive, breath-to-breath variability and COMFORT score when compared to pressure support (PS).Entities:
Mesh:
Year: 2012 PMID: 22481227 PMCID: PMC7094903 DOI: 10.1007/s00134-012-2535-y
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Basic clinical details on the patients
| ID | Age | PBW (kg) | Gender | Days on MV | Days in PICU | PaO2/FiO2 | Disease on admission | Reason for MV | Sedo-analgesic regime |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 months | 5.7 | Male | 71 | 98 | 422 | Congenital tracheal stenosis | ARF, respiratory ECMO | DZP 0.15 mg/kg b.i.d. MTD 0.15 mg/kg b.i.d. |
| 2 | 4 months | 4.8 | Female | 198 | 198 | 137 | Acute liver failure. Neonatal hemochromatosis | MOF, liver transplantation. Pulmonary fibrosis | MDZ 0.16 mg/kg/h FEN 1.6 μg/kg/h |
| 3 | 2 months | 4.6 | Male | 50 | 125 | 57 | Fallot tetralogy | Cardiogenic shock | MDZ 0.15 mg/kg/h KET 0.075 mg/kg/h |
| 4 | 6 months | 5.3 | Male | 41 | 51 | No arterial access | AoCo, IVC, pulmonary artery banding | Aspiration pneumonia | MDZ 1 mg/kg/h RMF 15 μg/kg/h |
| 5 | 3 months | 5 | Male | 8 | 15 | 176 | RSV bronchiolitis | ARDS | MDZ 0.12 mg/kg/h KET 0.07 mg/kg/h |
| 6 | 6 months | 7.2 | Male | 21 | 32 | 158 | Influenza A (H1N1), pneumocistys carinii pneumonia, hyper IgM immunodeficiency | ARDS | MDZ 0.25 mg/kg/h FEN 4 μg/kg/h |
| 7 | 7 weeks | 4.8 | Male | 9 | 18 | 178 | RSV bronchiolitis | ARDS | MDZ 0.07 mg/kg/h FEN 0.7 μg/kg/h |
| 8 | 2.5 years | 13.9 | Male | 10 | 22 | 140 | Necrotizing pneumonia, empyema | Neumothorax, bronchopleural fistula | DZP 0.25 mg/kg q.i.d MTD 0.33 mg/kg b.i.d. |
| 9 | 2 months | 5.3 | Male | 7 | 9 | 189 | RSV bronchiolitis | ARF | DZP 0.15 mg/kg t.i.d. MOR 0.1 mg/kg t.i.d. |
| 10 | 9 days | 4.5 | Male | 6 | 13 | No arterial access | RSV bronchiolitis | ARF | MDZ 0.25 mg/kg/h FEN 2.5 μg/kg/h |
| 11 | 7 months | 7.1 | Female | 76 | 92 | 258 | Acute liver failure | MOF, liver transplantation | MDZ 0.5 mg/kg/h MTM 30 mg/kg q.i.d. |
| 12 | 7 years | 23 | Male | 1 | 21 | 220 | Dilated cardiomyopathy | Excort® Berlin heart left VAD implantation | MTM 30 mg/kg q.i.d. |
AoCo Aortic coartation, ARDS acute respiratory distress syndrome, ARF acute respiratory failure, b.i.d. two times a day, DZP diazepam, ECMO extracorporeal life support, FEN fentanyl, ID patient identification number, IVC interventricular communication, KET ketamine, MDZ midazolam, MOF multiorgan failure, MOR morphine, MTD methadone, MTM metamizol, MV mechanical ventilation, PaO /FiO partial pressure oxygen in the blood/fraction of inspired oxygen at the beginning of the study, PBW predicted body weight, PICU pediatric intensive care unit, q.i.d. four times a day, RMF remifentanil, RSV respiratory syncytial virus, t.i.d. three times a day, VAD ventricular assist device
Fig. 1Definition of breath variables. Breath with trigger delay (Td): the onset of neural inspiration preceded that of inspiratory flow. EAdi Electrical activity of the diaphragm in microvolts, ΔEAdi maximum inspiratory EAdi difference, ΔEAdi EAdi change during trigger delay, EAdiTP EAdi–time-product during the neural inspiratory time, EAdiTP EAdi-time-product during the trigger delay, maxEAdi maximum EAdi per breath, minEAdi initial baseline inspiratory EAdi per breath, mTi mechanical inspiratory time, nTi neural inspiratory time, PEEP positive end expiratory pressure (in cmH2O)
Ventilator settings and ventilatory variables
| Ventilator settings/ventilatory variablesa | Ventilation periodsb |
| |||
|---|---|---|---|---|---|
| 1-PSb | 2-PSopt | 3-NAVA | 4-PSopt | ||
| Ventilator settings | |||||
| PS (cmH2O) | 12.4 (1.4) | 12.6 (1.6) | 13.0 (1.6) | 0.51 | |
| PEEP (cmH2O) | 5.8 (0.5) | 5.8 (0.6) | 5.8 (0.6) | 6.0 (0.6) | 0.30 |
| Flow trigger | 7.5 (2.3) | 7.3 (1.7) | 7.3 (1.7) | 7.3 (1.7) | 0.80 |
| NAVA level | 1.41 (0.23) | ||||
| NAVA trigger (μV) | 0.46 (0.12) | ||||
| FiO2 | 0.50 (0.4) | 0.51 (0.4) | 0.51 (0.4) | 0.51 (0.4) | 0.39 |
| Ventilatory variables | |||||
| | 5.5 (4.2–6.8) | 5.8 (4.6–7.0) | 5.6 (3.4–7.4) | 5.4 (4.2–6.5) | 0.13 |
| maxEAdi (μV) | 11.5 (7.1–19.7) | 14.3 (9.2–22.0) | 11.5 (6.7–17.3) | 13.6 (8.3–20.7) | 0.55 |
| | 19.6 (14.6–20.5) | 19.2 (15.2–21.6) | 18.0 (15.5–24.5) | 19.6 (14.6–21.0) | 0.85 |
| RR (bpm) | 44.4 (25.4–53.5) | 40.4 (29.3–51.9) | 37.1 (26.3–55.7) | 40.3 (30.2–53.2) | 0.92 |
| SpaO2 (%) | 97.5 (95.5–99.5) | 97.0 (95–99.0) | 98.0 (97.0–99.5) | 95.5 (94.5–97.5) | 0.02 |
| etCO2 (mmHg) | 32.8 (30.5–41.2) | 33.8 (31.6–40.9) | 34.2 (30.0–39.5) | 33.8 (30.0–41.2) | 0.93 |
etCO End tidal CO2 level, maxEAdi highest electrical activity of the diaphragm for the breath, NAVA neurally adjusted ventilatory assist, PEEP positive end expiratory pressure, P maximum airway pressure, PS baseline pressure support, PS optimized PS, RR respiratory rate, V tidal volume, SpaO oxygen saturation by pulsioxymetry
aVentilator setting data are given as the mean, with 1 standard deviation (SD) given in parenthesis; Ventilatory variables data are given as the median, with the 25–75 interquartile range (IQR) given in parenthesis
bFour sequential 10-min periods of data were recorded after 20 min of ventilatory stabilization (wash-out): 1-PSb, baseline pressure support (PS) with the ventilator settings determined by the attending physician; 2-PSopt, PS after optimization; 3-NAVA, NAVA level set so that maximum inspiratory pressure (P max) equaled P max in PS; 4-PSopt, same settings as in 2-PSopt. Post hoc analysis did not show significant differences between periods
Fig. 2Major asynchrony events. 1-PS Baseline pressure support (PS) with ventilator settings determined by the attending physician, 2-PS pressure support after optimization, 3-NAVA level set so that maximum airway pressure equaled maximum airway pressure during 1-PSb and 2-PSopt, 4-PS same pressure support settings as in 2-PSopt. N number of asynchrony events per minute. Values in the two upper figures are presented as the median with 25–75 % interquartile range (IQR). Values in the effect size figure are given as Pearson’s correlation coefficient, r, with the 95 % confident interval (CI). Horizontal dotted lines depict the limits for small, mild and large effect size, respectively.*p < 0.0125
Fig. 3Breath-to-breath breathing variability. CV Coefficient of variation, P maximum airway pressure per breath, b baseline, opt optimized, RR respiratory rate, V tidal volume, V /mTi mean inspiratory flow; for other abbreviations, see Figs. 1 and 2. Values are presented as the median with 25–75 % IQR, except for the effect size figure (bottom right corner) where values are given as Pearson’s correlation coefficient, r, with the 95 % CI; horizontal dotted lines depict the limits for small, mild and large effect size, respectively. *p < 0.0125
Fig. 4Neural drive to triggering and COMFORT score. ΔEAdi /ΔEAdi EAdi change during the triggering delay as a percentage of maximum inspiratory EAdi difference, EAdiTP /EAdiTP EAdi–time-product during the triggering delay as a percentage of the EAdi–time-product during neural inspiratory time, Td/nTi triggering delay as a percentage of neural inspiratory time (see Fig. 1). Values in two left figures are given as the median with 25–75 % IQR. COMFORT score dash–dotted line delimits light (above) from deep (below) sedation level. Values in the two right figures are given as Pearson’s correlation coefficient, r, with 95 % CI; horizontal dotted lines depict the limits for small, mild and large effect size, respectively.*p < 0.0125. # p = 0.0125. ## p = 0.050